NCT06231212View on ClinicalTrials.gov

Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

December 30, 2022

Conditions
Temporomandibular Disorder
Interventions
DRUG

ECa 233

Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.

DRUG

Ibuprofen

Ibuprofen group was given capsules containing 200 mg of ibuprofen

OTHER

Placebo

Placebo-controlled group received capsules containing 250 mg of lactose

Trial Locations (1)

Unknown

Chulalongkorn University, Bangkok

All Listed Sponsors
lead

Chulalongkorn University

OTHER

NCT06231212 - Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder | Biotech Hunter | Biotech Hunter